252. Phase II Study of MVA Expressing E6 and E7 of HPV16 in Patients with CIN2/3

Objectives: TG4001 (MVA-HPV-IL2) is based on the Modified Virus of Ankara (MVA) strain expressing E6 and E7 of Human Papillomavirus type 16 (HPV16) and human Interleukin-2 (IL-2). The efficacy of two different doses was tested in a randomized, phase II trial, conducted in patients with high-grade Cervical Intraepithelial Neoplasia (CIN2/3) related to HPV16.